The Efficacy and Toxicity of Gefitinib in Treating Non-small Cell Lung Cancer: A Meta-analysis of 19 Randomized Clinical Trials
Hongmei Wo, Jing He, Yang Zhao, Hao Yu, Feng Chen, Honggang Yi · Journal of Cancer · 2018
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · review · 2018
Abstract
Background: This meta-analysis evaluated the efficacy and toxicity of gefitinib with other commonly used drugs in different treatment settings and epidermal growth factor receptor (EGFR) mutation status.Methods: Nineteen randomize clinical trials (RCTs) of 6,554 patients with NSCLC were pooled in this meta-analysis by random-effects or fixed-effects model, whichever is proper.Results: In first-line therapy, gefitinib showed higher odds than chemotherapy (OR = 2.19, 95% CI: 1.20-4.01),but less than other targeted therapies (OR = 0.58, 95% CI: 0.38-0.88).As non-first-line therapy, the overall survival (OS) and progression-free survival (PFS) were similar between gefitinib and controls (HR = 1.00, 95% CI: 0.93-1.08;HR = 0.91, 95% CI: 0.72-1.15),respectively.With the regard to toxicity, the incidences of dry skin, rash and pruritus were higher in gefitinib compared with controls, while gefitinib significantly reduced the incidence of hematologic toxicity.Conclusion: Gefitinib might be more efficient than chemotherapy, but less efficient than other targeted therapies in ORR, especially in EGFR mutation-positive patients.Gefitinib can decrease the odds of hematologic toxicity compared to controls.Future studies, especially those with EGFR mutation-positive patients, will be needed to confirm our findings.
Open the resolved locator · 10.7150/jca.23356
Metadata licence: OpenAlex metadata (CC0)